CD-44 like protein
AssigneeHuman Genome Sciences, Inc.
InventorsJian Ni, Reiner Gentz, Patrick Dillon
Life of this patent
Estimating the term…
Abstract
The present invention concerns a novel CD44-like protein receptor. In particular, isolated nucleic acid molecules are provided encoding the CD44-like protein. CD44-like polypeptides are also provided, as are screening methods for identifying agonists and antagonists capable of enhancing or inhibiting CD44-like protein-mediated signaling. The invention further concerns therapeutic methods for treating diseases associated with processes mediated by CD44-like protein signaling.
Claims11
An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
- (a) a nucleotide sequence encoding a polypeptide comprising amino acids from about −21 to about 301 in SEQ ID NO:2;
- (b) a nucleotide sequence encoding a polypeptide comprising amino acids from about −20 to about 301 in SEQ ID NO:2;
- (c) a nucleotide sequence encoding a polypeptide comprising amino acids from about 1 to about 301 in SEQ ID NO:2;
- (d) a nucleotide sequence encoding a polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97520;
- (e) a nucleotide sequence encoding the mature CD44-like polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97520;
- (f) a nucleotide sequence encoding the CD44-like polypeptide extracellular domain;
- (g) a nucleotide sequence encoding the CD44-like polypeptide transmembrane domain;
- (h) a nucleotide sequence encoding the CD44-like polypeptide intracellular domain;
- (i) a nucleotide sequence encoding the CD44-like polypeptide receptor extracellular and intracellular domains with all or part of the transmembrane domain deleted;
- and
- (j) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g), (h), or (i).
An isolated CD44-like polypeptide having an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
- (a) amino acids from about −21 to about 301 in SEQ ID NO:2;
- (b) amino acids from about −20 to about 301 in SEQ ID NO:2;
- (c) amino acids from about 1 to about 301 in SEQ ID NO:2;
- (d) the amino acid sequence of the CD44-like polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97520;
- (e) the amino acid sequence of the mature CD44-like polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97520;
- (f) the amino acid sequence of the CD44-like polypeptide extracellular domain;
- (g) the amino acid sequence of the CD44-like polypeptide transmembrane domain;
- (h) the amino acid sequence of the CD44-like polypeptide intracellular domain;
- (i) the amino acid sequence of the CD44-like polypeptide extracellular and intracellular domains with all or part of the transmembrane domain deleted;
- and
- (j) the amino acid sequence of an epitope-bearing portion of any one of the polypeptides of (a), (b), (c), (d), (e), (f), (g), (h), or (i).
An isolated nucleic acid molecule comprising a polynucleotide having a sequence at least 95% identical to a sequence selected from the group consisting of:
- (a) the nucleotide sequence of clone HFFAC14R (SEQ ID NO:11);
- (b) the nucleotide sequence of clone HUVDE75R (SEQ ID NO:12);
- (c) the nucleotide sequence of clone HPRT158R (SEQ ID NO:13);
- (d) the nucleotide sequence of clone HHFCE82F (SEQ ID NO:14);
- (e) the nucleotide sequence of clone HE2CJ22R (SEQ ID NO:15);
- and
- (f) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), or (d) above.
Dependencies are inferred from the claim text.